samedan logo

 
 
spacer
home > ebr > spring 2003 > omega-3 fatty acids in the prevention of myocardial infarction
PUBLICATIONS
European Biopharmaceutical Review

Omega-3 Fatty Acids in the Prevention of Myocardial Infarction

Atherosclerosis is an arterial disease causing myocardial infarction and stroke, angina pectoris and sudden death. Atherosclerosis is responsible for about 60 per cent of total mortality in the US and about 22 per cent of the population has one or more types of cardiovascular disease (1). Atherosclerosis is therefore the main threat to life and health in industrialised society today.

Sclerosis means hardening, but this pathological feature is common and in general accepted as a rather benign disease: a normal ageing of the artery. Pathologists recognise two different types of atherosclerotic plaques: large, firm plaques consisting of organised connective tissue and small, soft plaques containing lipids and inflammatory cells. The large sclerotic plaques are stable, hard structures not likely to disrupt normal function, but nevertheless show up clearly on the angiogram.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Morten Bryhn, Director of R&D at Pronova Biocare

Dr Morten Bryhn is a specialist in cardiology and internal medicine, holding a PhD and an Assistant Professorship in the field of cardiology.

Dr Bryhn currently serves as Director of R&D at Pronova Biocare and has published around 100 scientific articles, several of which deal with the effects of omega-3 fatty acids.
 

spacer
Dr Morten Bryhn
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

The renewed Turkish Cargo Web Portal now offers you many conveniences with its new name ‘TK GO’

Turkish Cargo, the fastest-growing brand of the global air cargo industry, updated its web portal; a functional and user-friendly interface on Internet facilitating monitoring of all actions and providing the agents with customized solutions and facilitations.
More info >>

White Papers

Choosing the Right CMO for HPAPI Manufacturing

AMRI

Over the past few years a steady stream of contract manufacturing organizations (CMO) have added high potency active pharmaceutical ingredient (HPAPI) production capacity. The expansions give biopharma executives charged with selecting HPAPI production partners an unprecedented number of options, but all this choice creates a problem — which CMO should you pick when each is touting similar technical capabilities?
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement